• 2X Taq PCR Master Mix: Mechanism, Evidence, and Applications

  2026-07-18

  The 2X Taq PCR Master Mix (with dye) is a ready-to-use PCR reagent optimized for DNA amplification, featuring recombinant Taq DNA polymerase and integrated loading dye. It streamlines genotyping and cloning workflows and supports direct gel loading, with proven performance and defined mechanistic limits.

• Nifedipine (BAY-a-1040): Mechanistic Depth and Translational

  2026-07-17

  This thought-leadership article dissects the unique mechanistic roles of Nifedipine (BAY-a-1040) in translational research, bridging calcium influx inhibition, iron metabolism modulation, and the new frontiers illuminated by recent pregnane X receptor (PXR) activation studies. By synthesizing foundational biological insights with strategic guidance, we chart a pragmatic path for assay design and model selection in preclinical research, all while positioning APExBIO’s Nifedipine as a linchpin for next-generation discovery.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-07-17

  This study reveals that Chenodeoxycholic Acid (CDCA) protects against contrast-induced acute kidney injury (CI-AKI) by activating FXR, which transcriptionally upregulates KLF11 and suppresses the JAK2/STAT3 pathway. The mechanistic insights clarify the FXR-KLF11 axis as a promising prophylactic target, informing future research on nuclear receptor signaling and renal injury.

• Naloxone Hydrochloride: Advancing Opioid Receptor Antagonist

  2026-07-16

  Naloxone hydrochloride empowers researchers with unparalleled specificity in probing opioid receptor dynamics, from addiction models to neural stem cell assays. Its robust solubility and high purity streamline experimental workflows and enhance reproducibility, making it a cornerstone for translational neurobiology and behavioral pharmacology.

• Mitoxantrone in Anticancer Research: Workflows and Resistanc

  2026-07-16

  Mitoxantrone is a benchmark apoptosis inducer in B-CLL and a vital tool for dissecting multidrug resistance. This article details advanced protocol strategies, troubleshooting insights, and highlights the synergy between topoisomerase II inhibitors and ABCG2 modulation for translational oncology research.

• BGJ398 (NVP-BGJ398) in FGFR-Driven Oncology Research: Protoc

  2026-07-15

  BGJ398 (NVP-BGJ398) stands out as a highly selective FGFR tyrosine kinase inhibitor, enabling precise dissection of FGFR-driven pathways and apoptosis induction in cancer models. This article delivers practical workflows, comparative advantages, and troubleshooting strategies for maximizing experimental value in oncology research.

• Carbapenemase Transmission in CREC: Genomic and Epidemiologi

  2026-07-15

  This study examines the diversity, localization, and transmission dynamics of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China during the COVID-19 pandemic. Key findings include a high prevalence of plasmid-borne blaNDM-1, multidrug resistance, and efficient horizontal gene transfer, informing future antimicrobial resistance surveillance and experimental modeling.

• Genistein in Cytoskeleton-Dependent Autophagy & Cancer Assay

  2026-07-14

  Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) unlocks new frontiers in mechanotransduction and cancer chemoprevention by integrating precise protein tyrosine kinase inhibition with cytoskeleton-targeted workflows. This article presents actionable, protocol-ready insights and troubleshooting strategies for leveraging Genistein in cutting-edge apoptosis and proliferation assays.

• AO/PI Staining Solution: Fluorescent DNA Dyes for Viability

  2026-07-14

  AO/PI Staining Solution enables precise live/dead cell discrimination using dual fluorescent DNA dyes. This reagent from APExBIO provides robust, interference-free results for fluorescence-based cell counting and membrane integrity assays. It outperforms traditional viability stains in accuracy and reliability.

• Biomimetic Nanoplatforms for Synergistic TNBC Therapy: Innov

  2026-07-13

  Cheng et al. introduce a biomimetic nanoplatform integrating photothermal ablation with immune remodeling for metastatic triple-negative breast cancer (TNBC). By combining dendritic mesoporous silica nanoparticles, a photothermal agent, immune adjuvant, and immune checkpoint blockade peptide, the study demonstrates enhanced tumor targeting and durable immune activation. This approach addresses major challenges in TNBC therapy and signals new directions for multi-modal cancer nanomedicine.

• PA-824: Mechanistic Insights and Assay Design for Tuberculos

  2026-07-13

  Explore the unique mechanism of action of PA-824, a leading bicyclic nitroimidazole derivative, and discover how its dual targeting of Mycobacterium tuberculosis informs protocol optimization and rational combination strategies in tuberculosis research.

• Hydroxycinnamic Acids Disrupt COPII-STING Axis to Attenuate

  2026-07-12

  This study elucidates a novel mechanism by which hydroxycinnamic acids (HCAs) directly target the Sec24 B-site of the COPII cargo sorting machinery, thereby attenuating cGAS-STING-mediated inflammation and metabolic dysfunction in type 2 diabetes mellitus (T2DM) models. The results establish a structural and biochemical basis for HCA-rich traditional medicines in modulating ER-to-Golgi trafficking, offering new insights into inflammation control relevant to metabolic and autoinflammatory disorders.

• Septin4 Enhances Hypoxic Cardiomyocyte Injury via HIF-1α Deg

  2026-07-10

  This study uncovers a novel pathological mechanism in myocardial ischemia, demonstrating that Septin4 exacerbates hypoxia-induced cardiomyocyte apoptosis by promoting HIF-1α ubiquitination and degradation through the VHL pathway. These findings highlight a new regulatory axis influencing cardiac adaptation to hypoxia and open avenues for targeted modulation of the HIF pathway in ischemic heart disease.

• TRPV1 Antagonism and AMPK–SQSTM1 Feedback: New Frontiers in

  2026-07-09

  This thought-leadership article explores how AMG 9810, a potent TRPV1 antagonist from APExBIO, is accelerating the dissection of sensory neuron signaling and pain mechanisms, with new relevance in metabolic stress contexts. Integrating mechanistic insights from emerging autophagy research, we outline protocol parameters, translational implications, and strategic guidance for researchers seeking to bridge pain pathway studies with metabolic adaptation and tumor biology.

• Light-Inducible RNA-Releasing Protein Enables Precision Gene

  2026-07-09

  This study introduces a rationally engineered light-inducible RNA-releasing protein (LIRP) that allows spatiotemporal control of therapeutic gene expression in vivo. The technology is shown to be compatible with diverse gene therapy applications and delivery routes, offering a new level of safety and precision in regulating transgene activity, especially for metabolic and retinal diseases.

14666 records 1/978 page Next 12345 下5页 Last page